DNLI - Denali Therapeutics Inc.

QQQ $ 435.98 $ 8.58 (2.01 %)

DIA $ 386.87 $ 4.54 (1.19 %)

SPY $ 511.25 $ 6.26 (1.24 %)

TLT $ 89.88 $ 0.90 (1.01 %)

GLD $ 212.97 $ -0.17 (-0.08 %)

Previous Close

$ 17.14

Open

$ 17.12

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 17.04 - $ 17.89

52 Week Range

$ 14.56 - $ 33.31

Volume

860,159

Average Volume

Market Cap

2.35B

Beta (5Y Monthly)

$ 1.30

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-28-2024	12-31-2023	10-K
2	11-07-2023	09-30-2023	10-Q
3	08-08-2023	06-30-2023	10-Q
4	05-08-2023	03-31-2023	10-Q
5	02-27-2023	12-31-2022	10-K
6	11-03-2022	09-30-2022	10-Q
7	08-08-2022	06-30-2022	10-Q
8	05-05-2022	03-31-2022	10-Q
9	02-28-2022	12-31-2021	10-K
10	11-04-2021	09-30-2021	10-Q
11	08-04-2021	06-30-2021	10-Q
12	05-05-2021	03-31-2021	10-Q
13	02-26-2021	12-31-2020	10-K
14	11-05-2020	09-30-2020	10-Q
15	08-07-2020	06-30-2020	10-Q
16	05-07-2020	03-31-2020	10-Q
17	02-27-2020	12-31-2019	10-K
18	11-06-2019	09-30-2019	10-Q
19	08-06-2019	06-30-2019	10-Q
20	05-08-2019	03-31-2019	10-Q
21	03-12-2019	12-31-2018	10-K
22	11-08-2018	09-30-2018	10-Q
23	08-09-2018	06-30-2018	10-Q
24	05-11-2018	03-31-2018	10-Q
25	03-19-2018	12-31-2017	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Denali Therapeutics Completes Enrollment f...
05/01/2024 12:11:13

UBS Maintains Buy on Denali Therapeutics, ...
04/09/2024 16:05:59

UBS analyst Esther Rajavelu maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and lowers the price target from $70 to $32.

Denali Therapeutics Inc Files Prospectus R...
03/22/2024 20:05:07

- SEC Filing

Goldman Sachs Maintains Buy Rating for Den...
02/29/2024 17:00:14

Goldman Sachs Maintains Buy on Denali Ther...
02/29/2024 14:57:12

Goldman Sachs analyst Salveen Richter maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and lowers the price target fro...

4 Analysts Assess Denali Therapeutics: Wha...
02/28/2024 19:00:47

HC Wainwright & Co. Maintains Buy on Denal...
02/28/2024 17:27:17

HC Wainwright & Co. analyst Andrew Fein maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and lowers the price targ...

Wedbush Reiterates Outperform on Denali Th...
02/28/2024 12:50:10

Wedbush analyst Laura Chico reiterates Denali Therapeutics (NASDAQ:DNLI) with a Outperform and maintains $31 price target.

why-helix-energy-solutions-shares-are-trading-lower-by-11-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Why Helix Energy Solutions Shares Are Trad...
02/27/2024 18:18:56

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

norwegian-cruise-line-posts-strong-sales-joins-hims--hers-health-sterling-infrastructure-and-other-big-stocks-moving-higher-on-tuesday

Norwegian Cruise Line Posts Strong Sales, ...
02/27/2024 15:27:54

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.

Denali Therapeutics: Q4 Earnings Insights
02/27/2024 14:00:08

Denali Therapeutics Sees FY24 Operating Ex...
02/27/2024 13:21:20

Denali Therapeutics Q4 2023 GAAP EPS $(0.8...
02/27/2024 13:18:43

Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of...

Denali Therapeutics Announces $500M Privat...
02/27/2024 13:03:21

HC Wainwright & Co. Reiterates Buy on Dena...
02/22/2024 11:49:56

HC Wainwright & Co. analyst Andrew Fein reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $105 price...

Denali Therapeutics Was Informed By Its Pa...
02/16/2024 13:07:39

gene-therapy-player-regenxbios-rgx-121-marks-success-in-trial-yet-faces-challenges-in-a-crowded-market-analyst

Gene Therapy Player REGENXBIO's RGX-121 Ma...
02/12/2024 19:35:27

Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges po...

Denali Therapeutics Announces New Data And...
02/07/2024 13:22:48

New data show additional improvement and stabilization in clinical outcomes in MPS II with 104 weeks of tividenofusp alfa (DNL3...

Denali Therapeutics Announces 2024 Milesto...
01/08/2024 13:13:16

Complete enrollment in Denali-led, late-stage programs for MPS II and ALS, and establish commercial readiness Advance broad cli...

The Latest Analyst Ratings for Denali Ther...
12/13/2023 13:00:49